AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

Although some products like Imfinzi/Imjudo and Soliris underperformed, overall, the company’s performance was bolstered by significant gains in other segments, such as Symbicort and Ultomiris.

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca and Daiichi Sankyo's new ...

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

The guidance hike followed forecast-beating third quarter results, with revenues up 21% on a constant currency basis to 13.57 ...

This was accelerated by demand for its cancer blockbuster drugs Imfinzi, Tagrisso and Calquence. Analysts had expected core earnings per share at $2.04 on sales of $13.1 billion, according to a ...

Fiera Capital Corp trimmed its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.9% during the third quarter, according to the company in its most recent filing with the Securities and ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after ...